Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies
Authors
Keywords
Toxicities, Immunomodulatory drugs, Proteasome inhibitors, Daratumumab, Elotuzumab, Panobinostat
Journal
Current Hematologic Malignancy Reports
Volume 13, Issue 2, Pages 114-124
Publisher
Springer Nature
Online
2018-02-15
DOI
10.1007/s11899-018-0443-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carfilzomib-Associated Cardiovascular Adverse Events
- (2018) Adam J. Waxman et al. JAMA Oncology
- Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
- (2017) Bin Hu et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Paul J. Hesketh et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
- (2016) M. A. Dimopoulos et al. BLOOD
- Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma
- (2016) Kevin Barley et al. LEUKEMIA & LYMPHOMA
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical Management of Lenalidomide-Related Rash
- (2015) Sara M. Tinsley et al. Clinical Lymphoma Myeloma & Leukemia
- Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
- (2015) M. Merz et al. HAEMATOLOGICA
- Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma
- (2015) E. Wilson Grandin et al. JOURNAL OF CARDIAC FAILURE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
- (2015) S Atrash et al. Blood Cancer Journal
- Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
- (2015) M. Merz et al. HAEMATOLOGICA
- Late Cardiovascular Complications after Hematopoietic Cell Transplantation
- (2014) Eric J. Chow et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment
- (2014) C. Pawlyn et al. BLOOD
- Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma
- (2014) Min Jung Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview
- (2014) Andrzej J. Jakubowiak CANCER TREATMENT REVIEWS
- A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy in Patients With Multiple Myeloma
- (2014) Ting Bao et al. INTEGRATIVE CANCER THERAPIES
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-induced peripheral neuropathies in hematological malignancies
- (2014) Joost Louis Marie Jongen et al. JOURNAL OF NEURO-ONCOLOGY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
- (2014) Joerg Herrmann et al. MAYO CLINIC PROCEEDINGS
- Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis
- (2014) Yi Xiao et al. PLoS One
- Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy
- (2013) P. M. Voorhees et al. BLOOD
- Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis
- (2013) Beatrice Nardone et al. Clinical Lymphoma Myeloma & Leukemia
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
- (2013) Philippe Rodon et al. THROMBOSIS AND HAEMOSTASIS
- Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy
- (2012) Norisato Hashimoto et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma
- (2012) Claudio Cartoni et al. SUPPORTIVE CARE IN CANCER
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
- (2011) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Management of treatment-emergent peripheral neuropathy in multiple myeloma
- (2011) P G Richardson et al. LEUKEMIA
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
- (2010) S. Bringhen et al. BLOOD
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
- (2010) Meletios A. Dimopoulos et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
- (2010) Annemiek Broyl et al. LANCET ONCOLOGY
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
- (2010) Michel Delforge et al. LANCET ONCOLOGY
- Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies
- (2010) Guido Cavaletti et al. LEUKEMIA & LYMPHOMA
- A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
- (2010) Debra L. Barton et al. SUPPORTIVE CARE IN CANCER
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
- (2009) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- Complementary Therapies for Neuropathic and Neuralgic Pain
- (2008) Max H. Pittler et al. CLINICAL JOURNAL OF PAIN
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started